Japan
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
Blackstone to buy leading Japanese CRO in latest move by a global private equity group to build a position in Japan’s life sciences space.
Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.
US private equity group to buy Japanese pharma firm in a transaction scheduled to close by September that marks owner's exit from pharma.
Sun Pharma sees opportunities for Antibe’s otenaproxesul in the US and emerging markets and aims to get the clinical hold on the novel NSAID lifted. The firm is also focusing on its specialty business in Japan, amid pricing challenges for long-listed products.
Mostly strong global sales of mainstay drugs, along with a forex boost, helped Japan's major pharma firms in the fiscal third quarter and calendar year.
Leading Japanese pharma firm names first ever woman chief exec as it reports a jump in operating profit in the fiscal nine months, led by Entyvio.
The Japanese pharma firm has sued a politician claiming defamatory actions on social media around its novel COVID-19 vaccine.
US firm is using a mix of partnerships and direct presence to build its operations in Asia, which will focus on novel drugs.
The struggling Japanese pharma group is aiming to grow its new cell therapy business in the US and Japan to $2.3bn by the late 2030s.
Several Japanese pharma firms are developing use cases for GenAI beyond R&D, in some cases boosting their capabilities with an Nvidia-backed supercomputer platform.
The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.
Takeda, Astellas, Daiichi Sankyo, Chugai, Shionogi all revised their annual forecasts upwards due to forex rate impact and saw mostly solid overseas sales growth in the fiscal first half.
Multiple Japanese ventures presented updates on their novel pipeline assets and modalities at BioJapan, including cell and gene therapies and combination treatments, despite lingering financing challenges.
Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2024, held in Tokyo on 22 October.
Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.
Following consideration by our independent expert judging panel, the final shortlist of entries has now been revealed for the Citeline Japan Awards 2024. Join us at the event in Tokyo on 22 October!